Assessing predictors of drug-induced torsade de pointes

被引:214
作者
Belardinelli, L
Antzelevitch, C
Vos, MA
机构
[1] CV Therapeut, Palo Alto, CA 94304 USA
[2] Masonic Med Res Lab, Utica, NY 13501 USA
[3] Univ Med Ctr Utrecht, NL-3584 CG Utrecht, Netherlands
关键词
LONG-QT SYNDROME; POTENTIAL DURATION PROLONGATION; EARLY AFTERDEPOLARIZATIONS; INTERVENTRICULAR DISPERSION; VENTRICULAR-ARRHYTHMIAS; TRANSMURAL DISPERSION; TRIGGERED ACTIVITY; DELAYED RECTIFIER; CELLULAR BASIS; DYNAMIC-MODEL;
D O I
10.1016/j.tips.2003.10.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Torsades de pointes (TdP) is a malignant polymorphic ventricular tachyarrhythmia that can be caused by drugs that induce ellectrophysiological changes. Although the number of drugs known to cause TO has increased in recent years, there is no cell-based assay, in vitro heart preparation or animal model that predicts the potential of a drug to induce TdP in humans. Nevertheless, certain electrophysiological events are known to be associated with the development of TdP. For example, a drug that prolongs action potential duration, induces early after depolarizations and ectopic beats, and increases dispersion of ventricular repolarization is likely to cause TdP. By contrast, a drug that does not induce these changes is unlikely to cause TdP. The exact relationship between these electrophysiological events and the development of TdP has not been defined, but the potential of a drug to elicit these events might predict its pro-arrhythmic risk.
引用
收藏
页码:619 / 625
页数:7
相关论文
共 59 条
  • [1] Cellular basis for dispersion of repolarization underlying reentrant arrhythmias
    Akar, FG
    Laurita, KR
    Rosenbaum, DS
    [J]. JOURNAL OF ELECTROCARDIOLOGY, 2000, 33 : 23 - 31
  • [2] [Anonymous], CARDIAC ELECTROPHYSI
  • [3] Cellular mechanisms underlying the long QT syndrome
    Antzelevitch, C
    Shimizu, W
    [J]. CURRENT OPINION IN CARDIOLOGY, 2002, 17 (01) : 43 - 51
  • [4] The M cell: Its contribution to the ECG and to normal and abnormal electrical function of the heart
    Antzelevitch, C
    Shimizu, W
    Yan, GX
    Sicouri, S
    Weissenburger, J
    Nesterenko, VV
    Burashnikov, A
    Di Diego, J
    Saffitz, J
    Thomas, GP
    [J]. JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 1999, 10 (08) : 1124 - 1152
  • [5] Optical mapping of drug-induced polymorphic arrhythmias and torsade de pointes in the isolated rabbit heart
    Asano, Y
    Davidenko, JM
    Baxter, WT
    Gray, RA
    Jalife, J
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 29 (04) : 831 - 842
  • [6] PROARRHYTHMIC EFFECTS OF THE CLASS-III AGENT ALMOKALANT - IMPORTANCE OF INFUSION RATE, QT DISPERSION, AND EARLY AFTERDEPOLARIZATIONS
    CARLSSON, L
    ABRAHAMSSON, C
    ANDERSSON, B
    DUKER, G
    SCHILLERLINHARDT, G
    [J]. CARDIOVASCULAR RESEARCH, 1993, 27 (12) : 2186 - 2193
  • [7] ACTION POTENTIALS, AFTERPOTENTIALS, AND ARRHYTHMIAS
    CRANEFIELD, PF
    [J]. CIRCULATION RESEARCH, 1977, 41 (04) : 415 - 423
  • [8] Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients
    Curtis, LH
    Ostbye, T
    Sendersky, V
    Hutchison, S
    Lapointe, NMA
    Al-Khatib, SM
    Yasuda, SU
    Dans, PE
    Wright, A
    Califf, RM
    Woosley, RL
    Schulman, KA
    [J]. AMERICAN JOURNAL OF MEDICINE, 2003, 114 (02) : 135 - 141
  • [9] DALNONCOURT CN, 1982, BRIT HEART J, V48, P213
  • [10] DAY CP, 1990, BRIT HEART J, V63, P342